Glutamatergic Deficits in Schizophrenia – Biomarkers and Pharmacological Interventions within the Ketamine Model

BACKGROUND: The observation that N-methyl-D-aspartate glutamate receptor (NMDAR) antagonists such as ketamine transiently induce schizophrenia-like positive, negative and cognitive symptoms has led to a paradigm shift from dopaminergic to glutamatergic dysfunction in pharmacological models of schizo...

Descripción completa

Detalles Bibliográficos
Autores principales: Haaf, Moritz, Leicht, Gregor, Curic, Stjepan, Mulert, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142413/
https://www.ncbi.nlm.nih.gov/pubmed/29929462
http://dx.doi.org/10.2174/1389201019666180620112528

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142413/
https://www.ncbi.nlm.nih.gov/pubmed/29929462
http://dx.doi.org/10.2174/1389201019666180620112528

Ejemplares similares